Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Pietro OrlandoGiuseppe LicciDonald KuitcheAndrea MatucciAlessandra VultaggioOreste GalloGiandomenico MaggiorePublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2023)
ESS and dupilumab were effective at reducing CRSwNP inflammatory burning. CRSwNP smell impairment cannot be attributed only to olfactory cleft obstruction and other mechanisms may be involved. Dupilumab acts systemically with poor correlation with NPS. As of today, dupilumab appears to be more suitable for elderly patients with anesthesiological contraindications and/or several previous surgeries, while ESS may represent the first-line choice in surgery-naive patients.
Keyphrases
- atopic dermatitis
- chronic rhinosinusitis
- minimally invasive
- coronary artery bypass
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- systematic review
- surgical site infection
- prognostic factors
- peritoneal dialysis
- hiv infected
- ultrasound guided
- coronary artery disease
- acute coronary syndrome